01.27.10
Novartis 4Q
4Q Revenues: $12.9 billion (+8%)
4Q Earnings: $2.3 billion (+54%)
FY Revenues: $44.3 billion (+7%)
FY Earnings: $8.5 billion (+4%)
Comments: In the quarter, Pharmaceutical sales were up 21% to $7.8 billion. Vaccines and Diagnostics revenue was up 182% to $1.4 billion and included $1.0 billion of H1N1 pandemic vaccine and adjuvant sales. Sandoz (generic) revenue was up 19% to $2.1 billion. Consumer Health revenues were up 20% to $1.6 billion. For the year, Pharmaceutical sales were up 8% to $28.5 billion, Vaccines and Diagnostics sales were up 38% to $2.4 billion, Sandoz sales were $7.5 billion (-1%) and Consumer Health sales were flat at $5.8 billion. Top-performing regions included Europe ($18.4 billion, +10% lc) and the U.S. ($14.3 billion, +11% lc) as well as the top six emerging markets ($4.0 billion, +17% lc) of Brazil, China, India, Russia, South Korea and Turkey.
4Q Revenues: $12.9 billion (+8%)
4Q Earnings: $2.3 billion (+54%)
FY Revenues: $44.3 billion (+7%)
FY Earnings: $8.5 billion (+4%)
Comments: In the quarter, Pharmaceutical sales were up 21% to $7.8 billion. Vaccines and Diagnostics revenue was up 182% to $1.4 billion and included $1.0 billion of H1N1 pandemic vaccine and adjuvant sales. Sandoz (generic) revenue was up 19% to $2.1 billion. Consumer Health revenues were up 20% to $1.6 billion. For the year, Pharmaceutical sales were up 8% to $28.5 billion, Vaccines and Diagnostics sales were up 38% to $2.4 billion, Sandoz sales were $7.5 billion (-1%) and Consumer Health sales were flat at $5.8 billion. Top-performing regions included Europe ($18.4 billion, +10% lc) and the U.S. ($14.3 billion, +11% lc) as well as the top six emerging markets ($4.0 billion, +17% lc) of Brazil, China, India, Russia, South Korea and Turkey.